Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies,...

Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis NEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...

Monoclonal Antibodies Market revenue to cross USD 380 Bn by 2027: Global Market Insights Inc. Selbyville, Delaware, June 08, 2021 (GLOBE NEWSWIRE) -- According to latest report “Monoclonal Antibodies Market by Type (Fully Human, Humanized, Chimeric), Application (Oncology, Autoimmune...